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Abstract: Long bone nonunion in the context of congenital pseudar-
throsis or carcinologic resection (with intercalary bone allograft implan-
tation) is one of the most challenging pathologies in pediatric
orthopedics. Autologous cancellous bone remains the gold standard
in this context of long bone nonunion reconstruction, but with several
clinical limitations.We then assessed the feasibility and safety of human
autologous scaffold-free osteogenic 3-dimensional (3D) graft (derived
from autologous adipose-derived stem cells [ASCs]) to cure a bone
nonunion in extreme clinical and pathophysiological conditions.
Human ASCs (obtained from subcutaneous adipose tissue of 6
patients and expanded up to passage 4) were incubated in osteogenic
media and supplemented with demineralized bone matrix to obtain the
scaffold-free 3D osteogenic structure as confirmed in vitro by histo-
morphometry for osteogenesis and mineralization. The 3D ‘‘bone-like’’
structure was finally transplanted for 3 patients with bone tumor and 3
patients with bone pseudarthrosis (2 congenital, 1 acquired) to assess the
clinical feasibility, safety, and efficacy. Although minor clones with
structural aberrations (aneuploidies, such as tri or tetraploidies or clonal
trisomy 7 in 6%–20% of cells) were detected in the undifferentiated
ASCs at passage 4, the osteogenic differentiation significantly reduced
these clonal anomalies. The final osteogenic product was stable, did not
rupture with forceps manipulation, did not induce donor site morbidity,
and was easily implanted directly into the bone defect. No acute (<3
mo) side effects, such as impaired wound healing, pain, inflammatory
reaction, and infection, or long-term side effects, such as tumor devel-
opment, were associated with the graft up to 4 years after transplan-
tation.
We report for the first time that autologous ASC can be fully
differentiated into a 3D osteogenic-like implant without any scaffold.
We demonstrated that this engineered tissue can safely promote osteo-
genesis in extreme conditions of bone nonunions with minor donor site
morbidity and no oncological side effects.
(Medicine 94(50):e2220)
Abbreviations: 3D = three-dimensional, ASCs = adipose-derived
stem cells, ATMP = Advanced Therapy Medicinal Products, DBM
= demineralized bone matrix, ECM = extracellular matrix, FACS =
fluorescence-activated cell sorting, FISH = fluorescence in situ
hybridization, GMP = good manufacturing practice, MSCs =
mesenchymal stem cells, P4 = passage 4.
INTRODUCTION
L ong bone nonunion in the context of congenital pseudar-throsis (1 in 140,000–250,000 births) or carcinologic resec-
tion (1% of all cancers, and an estimated incidence of 6/million
per y, requiring intercalary allograft reconstruction) is one of the
most challenging pathologies in pediatric orthopedics. Patho-
physiological conditions and neo-adjuvant chemotherapy cause
nonhealing bone in 15% to 55% of patients after allograft or
prosthesis reconstruction.1–6 The current gold standard for bone
nonunion remains autologous cancellous bone graft from iliac
crest (in most cases and in a small bone defect) containing bone
marrow mesenchymal stem cells (MSCs), but available
quantities are limited and the harvesting procedure is burdened
by comorbidities.7,8 The use of osteoinductive materials such as
demineralized bone matrix (DBM) and bone morphogenetic
proteins (BMPs) to overcome the lack of osteoinduction and
osteogenic properties of synthetic or human materials remains
relatively prohibitive in the pediatric context. The principle of
caution is applied for derived bone growth factors because they
have been implicated in the tumor process, and specific studies
with long-term follow-up for safety are lacking.6,9–15 Tissue
engineering and cell therapy using MSCs have raised the
possibility of implanting living tissue for bone reconstruction.
Adipose-derived stem cells (ASCs) demonstrate several advan-
tages over those from bone marrow (considered the gold
standard), including a less invasive harvesting procedure, a
higher number of stem cell progenitors from an equivalent
amount of tissue harvested, increased proliferation and differ-
entiation capacities, and better angiogenic and osteogenic prop-
erties in vivo.16–24
Critical size bone reconstruction using stem cells also
remains limited by the large size ofbonedefects andconsequently
the size of the engineered implant requiring a scaffold. Tissue
engineering can potentially provide treatment alternatives for
conventional large bone defects. The application of different
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combinations of osteoconductive biomaterials, osteoprogenitor
cells, and growth factors directly into the defect holds great
potential for achieving bone healing in stringent and difficult
conditions.Biomaterials should ideally possess properties such as
mechanical strength, biodegradability, support. and stem cell
differentiation with regard to mimicking bone-forming com-
ponents to eliciting specific cellular responses and providing
an ideal environment for bone formation. To date, no synthetic or
biological scaffolds fulfil all these criteria since they can be
influenced by the surrounding microenvironments or cause
immunological problems.25,26
Several scaffold-free systems have been investigated, but
creating sufficient thickness to fill a critical size bone defect is
difficult.27 We developed a graft made of scaffold-free auto-
logous ASCs differentiated into a 3-dimensional (3D) osteo-
genic structure with DBM.28 We previously demonstrated the
safety and efficacy of this graft to cure a femoral critical size
bone defect in a pig preclinical nonunion model at 6 months
postimplantation.28 Complete stem cell differentiation in an
osteogenic 3D structure significantly improved the efficacy of
bone reconstitution (by promoting angiogenesis and osteogen-
esis) and the safety through a lower risk of growth factor
release.29 After osteogenic differentiation, human and pig ASCs
demonstrated similar in vitro (vascular endothelial growth
factor release and viability in hypoxic conditions) and in vivo
(angiogenicity and osteogenicity with cellular engraftment and
graft mineralization, respectively) properties.29,30
Subsequent to the preclinical experiments, we then
assessed the feasibility (ie, the reproducibility of manufacturing
of 3D graft clinical batch) and safety (ie, the risk of MSCs
within the tumor environment and pediatric context) of human
autologous 3D osteogenic grafts to cure bone nonunion in
extreme clinical and pathophysiological conditions. We also
investigated the bone consolidation at a minimum of 1 year
after reconstruction.
METHODS
This study was performed according to the Belgian Min-
istry of Health (AFMPS) guidelines for hospital exemption (and
obtained the authorization by the national central authorities as
the clinical number studies: ATMP-HE004) as per the Article 28
of European Regulation 1394/2007 on Advanced Therapy
Medicinal Products. To qualify for this so-called hospital
exemption (HE), the advanced therapy concerned should meet
the following criteria: preparation on a nonroutine basis, prep-
aration according to specific quality standards, use in a hospital,
use under the exclusive responsibility of a medical practitioner,
and comply with an individual medical prescription for a
custom-made product for an individual patient As such, the
legislator intends to provide patients the possibility to benefit
from a custom-made, innovative individual treatment in the
absence of valid therapeutic alternatives. All procedures for
tissue procurement and clinical studies (for children patients)
were approved by the Ethical Committee of the Medical Faculty
(Universite Catholique de Louvain) as the national authoriz-
ation number: B40320108542. All patients (parents of the
children) signed the consent to participate to the study after
verbal and written information by the principal investigator of
the study. All consents were included and archived in the Case
Report Form for each patient (and for a duration of 30 y).
All materials were obtained from Lonza (Verviers, Bel-
gium), Sigma-Aldrich (St Louis, MO), or Invitrogen (Carlsbad,
CA) unless otherwise noted.
Scaffold-free 3D Graft From Human ASCs and
DBM Combination
Study Design and Patients
Between 2010 and 2012, 6 young patients were included in
the study (Table 1). Three male patients with bone tumors (2
osteosarcomas for patients #1 and #2 and 1 Ewing sarcoma for
patient #3 characterized by several clonal cytogenetic altera-
tions). Preoperative chemotherapy was applied for a mean
duration of 7 and 10 months before tumor resection. The ana-
tomical reconstitution was performed with a metallic (Phenix)
prosthesis and a human osteochondral allograft, respectively.
A 3D stem cell autograft was also proposed for 3 patients
with bone nonunions due to congenital pseudarthrosis (n¼ 2 for
patients #4 and 5) or acquired pseudarthrosis (in the context of
erythroblastopenia, n¼ 1 for patient #6) that was untreatable
with classical treatments such as surgery (eg, curettage,
elongation, Fassier–Duval telescopic system, intramedullary
fixation, and Ilizarov fixation), iliac crest autograft, and
DBM alone. The autologous adipose stem cell transplant was
TABLE 1. Mesenchymal Stem Cell Harvesting and Processing for Clinical Application
Patient Location Sex Age (y)
Adipose
Volume (g)
Time of
Proliferation
to End of P3 (d)
No. cells at
P3 (106)
Time Between P4 and
Transplantation
of 3D Graft (d)
1 Left femur M 10 2.10 29 12 52
2 Left tibia M 11 0.32 38 9 42
3 Right tibia M 12 1.12 42 18 101
4 Left ulna M 6 0.67 42 19 88
5 Left tibia F 6 0.24 47 18 80
6 Right tibia M 13 7 45 20 66
The anatomical reconstitution was performed with a metallic prosthesis (Phenix, patient 1) and a human osteochondral allograft (patients 2 and 3).
Tumors of patients 1 and 2 were classified as conventional high-grade osteoblastic osteosarcoma and included in the EURAMOS protocol (European
and American Osteosarcoma Study Group: chemotherapy with methotrexate, doxorubicin, and cisplatin). Patient 3 had a high-grade Ewing sarcoma
and was included in the Euro-Ewing protocol (chemotherapy with vincristine, ifosfamide, doxorubicin, VP-16). Adipose subcutaneous tissue was
procured surgically (at the time of tumor biopsy for patients 1–3) or by aspiration with a syringe (for patients 4–6) at the leg for all patients except in
the abdominal region for patient 4.
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proposed after a mean of 35.3 months after diagnosis of bone
nonunion without success by conventional therapies.
Clinical Grade Manufacturing of the 3D Graft
The Endocrine Cell Therapy Unit (Center of Tissue and
Cell Therapy, Cliniques Universitaires Saint-Luc, Brussels,
Belgium) is recognized as a clinical laboratory for isolating
ASCs by the Belgian Federal Agency for Medicines and Health
Products. All procedures for ASC isolation and expansion were
performed in air-laminated flow grade A located in clean room
grade B (validated annually by ICCE SA, Elsene, Belgium), in
accordance with the Belgium Ministry of Health recommen-
dations and European directives (regulation no. 1394/2007 for
advanced cell therapy products). The environment for cellular
culture was controlled by weekly particle counting (in static and
dynamic conditions; Lasair II Particle Counter, ParticleMeasur-
ing Systems Germany GmbH, Darmstadt, Germany) and micro-
biological testing at each manipulation, as recorded in the
‘‘Graft Report.’’
To isolate human ASCs, a mean of 1.9 2.6 g of fatty
tissue was harvested by a simple subcutaneous biopsy from 6
patients (Table 1) after informed consent and serologic screen-
ing.31 ASC isolation (with GMP collagenase 0.075 g; 8000 PZ
U/L; Serva Electrophoresis GmbH, Heidelberg, Germany),
expansion, and differentiation were performed in line with good
manufacturing practices (GMPs) and the ISO 9001–2008 qual-
ity management system. ASCs were then isolated and expanded
in the proliferation medium (Dulbecco modified Eagle medium
supplemented with 10% heat-inactivated and viral-tested fetal
bovine serum certified by the US Department of Agriculture;
Life Technologies, Grand Island, NY) up to passage 4 (P4)
(after sequential trypsinizations).28,29 At P4, ASCs were incu-
bated (in 150-cm2 culture flask) in osteogenic medium com-
posed of the proliferation medium supplemented with
dexamethasone (1mM), sodium ascorbate (50mg/mL), and
sodium dihydrophosphate (36mg/mL). After 15 to 18 days
of ASC incubation, DBM was added (10mg/mL) to create
the 3D scaffold-free graft.28
Human DBM was provided by the University Tissue Bank
(University Clinical Hospital, Saint-Luc, Brussels, Belgium)
and was produced from multiorgan human donors. Diaphysis of
femoral or tibial bone was cut and ground into particles between
200 and 700mm for demineralization treatment. DBM was
performed by grinding cortical bones from selected human
donors (<45 y old; 7 donors were used for this experimental
protocol). First, human bone tissue was defatted by acetone
(99%) bath overnight, followed by washing in demineralized
water for 2 hours. Decalcification was performed by immersion
in 0.6N HCl for 3 hours (20mL solution per gram of bone)
under agitation at room temperature. Then, demineralized bone
powder was rinsed with demineralized water for 2 hours and the
pH was controlled (normal ph between 7.00 and 7.84). If the pH
was too acidic, DBM was buffered with phosphate solution at
0.1M under agitation. Finally, DBM was freeze-dried and
weighed. The DBM was sterilized with 25 kGy by gamma
irradiation at 808C. The osteogenic properties of DBM were
assessed by the residual level of calcium concentration after the
demineralization process (measured by calcium extraction con-
tained in a mean of 1.3 g of DBM vs nondemineralized bone
powder from each donor); and the osteoinduction by in vivo
implantation in paravertebral musculature of nude rats (male,
6–8 wks old) to quantify the new bone formation (presence of
bone marrow, osteoblast activity, and new bone formation) by
histomorphometry (a standard 300 cross-grid for point counting
under a microphotography at 10magnification; 4 nonoverlap-
ping areas per slide were studied) at 1 month postimplantation
for demineralized versus non-DBM.
The 3D graft (was ready for implantation right off the
plastic dish) was implanted after a mean of 71.5 22.3 days of
incubation in osteogenic medium (after P4) (Fig. 1). The day of
implantation, the 3D graft was rinsed 3 times with transplan-
tation medium (CMRL; Mediatec Inc., Manassas, VA) without
phenol red and without antibiotics or sera. The graft was finally
placed in a sterile culture flask enclosed in 3 sterile plastic bags.
The graft was then transferred at room temperature, in less than
15minutes, to the operating room for implantation.
Quality Control of Graft Release
The ASCs (at P4) were tested in specific medium to assess
the capacity of differentiation towards the 3 main mesenchymal
lineages. Confluent cultures of ASCs were induced to undergo
adipogenesis, chondrogenesis, or osteogenesis by replacing the
proliferation medium with specific induction media: for adipo-
genesis, Iscove modified Dulbecco medium with 20% fetal calf
serum, 2mM L-glutamine, bovine insulin (5mg/mL), indo-
methacin (50mM), 3-isobutyl-1-methyl-xanthine (0.5mM),
dexamethasone (1mM), penicillin (100U/mL), and streptomy-
cin (100mg/mL); for osteogenesis, proliferation medium
supplemented with dexamethasone (1mM), sodium ascorbate
(50mg/mL), and sodium dihydrophosphate (36mg/mL); and for
chondrogenesis, proliferation medium supplemented with
1mM dexamethasone,10 ng transforming growth factor-b3,
40mg/mL L-proline, 50mg/mL sodium ascorbate, 36mg/mL
sodium dihydrophosphate, 100mg/mL sodium pyruvate, and
100mL/mL insulin-transferrin-selenium þ premix. The med-
ium was replaced every 2 days up to demonstrate the differ-
entiation by oil red staining (for neutral lipids), alizarin red (for
CaPO4 deposition), and osteocalcin (for bone phenotype) and
finally alcian blue (for proteoglycans), respectively.28
At P4, each batch of ASCs was also characterized by
fluorescence-activated cell sorting (FACS). The specific cell
surface marker profile was analyzed for CD44 (PE mouse
antihuman CD44, BD Bioscience, Franklin Lakes, NJ),
CD45 (FITC mouse antihuman CD45, BD Bioscience),
CD73 (FITC mouse antihuman CD73, BD Bioscience),
CD90 (PE mouse antihuman CD90, BD Bioscience), and
CD105 (FITC mouse antihuman CD105, BD Bioscience).
ASCs were stained with saturating amounts of monoclonal
antibody. At least 10,000 events were analyzed by flow cyto-
metry (FACScan, BD Biosciences) with CellquestPro software.
Results were expressed in mean fluorescence intensity. In
control, hematopoietic stem cells were analyzed.
When the final scaffold-free 3D graft was obtained with
the optimal DBM concentration (ASCs þ 10mg/mL), the
cellular viability and the graft integrity were determined by a
histomorphological score including the cellular, extracellular
matrix, and DBM contents: (DBM–ECM)/viable cells. A 20-
mm2 biopsy (day of the transplantation) was fixed in 4%
paraformaldehyde overnight. We normalized the integrity of
the 3D graft by the (DBM–ECM)/viable cells ratio between1
and þ1.28
Graft Safety
Cytogenetic stability was studied by karyotype and fluor-
escence in situ hybridization (FISH) analyses at P4 (undiffer-
entiated and differentiated) of ASCs from the 6 patients to
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assess the oncogenic safety of the cellular components of the 3D
graft. Metaphase chromosomes were obtained according to
standard protocols from cultured cells (ASCs) in the exponen-
tial growth phase after P4.32 Twenty Giemsa-Trypsin-Wright
banded metaphases were analyzed, and karyotypes were
reported according to the last 2013 International System for
Human Cytogenetics Nomenclature. The FISH experiment was
performed according to standard protocols to detect aneuploidy
of chromosomes 7 and 8 using CEP7/D7Z1 (SpectrumGreen or
SpectrumOrange) or CEP8/D8Z2 (SpectrumOrange or Spec-
trumGreen) probes (Abbot Molecular, Ottignies/Louvain-la-
Neuve, Belgium).32 For the patient with tumors, specific probes
according to the initial genomic alterations detected in the
tumors were tested in the P4 ASCs (undifferentiated and
differentiated): LSI 9p21/CEP 9 (Abbot SA, Wavre, Belgium),
ON MDM2/SE 12 (Kreatech Diagnostics, Amsterdam, the
Netherlands), LSI-RB1/13q1 42 (Abbot SA), LSI TP53/CEP
17 (Abbot SA), LSI EWSR1 (Abbot SA), and LSI-FLI1 and
EWSR1 (Cytocell, Cambridge, UK). At least 100 nuclei were
counted, and the thresholds were calculated following the
inverse beta law, with a confidence interval of 99.9%.
Mycoplasma and endotoxin assays were also performed, as
per current GMP guidelines, by TEXCELL SA (Evry, France)
on cellular samples collected at P4 for undifferentiated and
osteogenic cells (the last sample prior graft delivering). Micro-
biological testing was repeatedly performed at each media
change (twice a week during the entire manufacturing of the
graft) for aerobia, anaerobia, moisture, and yeast by BACTEC
assays.
In-process controls (on cellular samples collected at
P4 for undifferentiated and osteogenic cells up to the last
sample before graft delivery) based on safety tests found no
microbiological or mycoplasm contamination and no endo-
toxin contents for any manufacturing batch. Therefore, all
manufactured 3D grafts fulfilled the release criteria for
implantation.
FIGURE 1. Protocol to obtain a 3-dimensional (3D) osteogenic graft made of adipose-derived stem cells (ASCs). Human ASCs were
isolated following digestion of subcutaneous adipose tissues, expanded up to passage 4 (P4), and finally differentiated in 2 phases. The
osteogenic differentiation was induced to create a 3D structure by the addition of demineralized bone matrix (DBM). The optimal
concentration of DBM was adjusted with the anticipated function of the 3D construction to produce a sufficiently stable graft for
manipulation by forceps.
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The 3D Graft Implantation and Outcome
In case of tumor resection (patients 1–3), the 3D graft was
placed directly at the junction between the native host bone and
the bone allograft or the growing prosthesis. In case of bone
nonunion, the 3D osteogenic graft was modeled to the ideal size
of the bone defect and put directly into the hole without any
fixation material.
The primary outcomes of the clinical trial were safety and
feasibility of the procedure assessed at 12 months after implan-
tation. The safety was studied in terms of adverse events (local
or systemic) with clinical (inflammation, wound infection) and
biological (C-reactive protein, fibrinogen, white blood cell
count) assessments on a specific schedule: 2 times per week
during the first month and once per month from month 1 to 12
postimplantation. The safety was also investigated by x-ray
between 12 and 39 months posttransplantation to assess any
secondary ectopic malignant tissue development.
The feasibility study was based on the ability to reprodu-
cibly obtain a 3D structure from autologous stem cells and
allogenic DBM, the respect of the timing between the adipose
tissue procurement and the surgical intervention (especially for
tumor resection in combination with the chemotherapy presur-
gery), the capacity to produce enough 3D grafts to fill a large
bone defect, and the surgical handling of the 3D graft being
clinically relevant for large-scale application.
The secondary outcomes were the efficacy for bone tissue
consolidation at the site of bone nonunion (radiologically
assessed) and patient satisfaction based on quality of life (eg,
walking, pain).
Statistical Analysis
Results are expressed as mean standard deviation. The 1-
sample Kolmogorov–Smirnov test and Q-Q plots were used to
assess the normal distribution of values. Statistically significant
differences between groups were tested by 1-way analysis of
variance with the Bonferroni post hoc test. Statistical tests were
performed with PASW 18 (SPSS; IBM, Armonk, NY); P< 0.05
was considered significant.
RESULTS
At P4, human ASC characteristics were confirmed by differ-
entiation in the adipose, osteogenic, and chondrogenic phenotypes,
and by a significant shift in the mean fluorescence intensity curve
(FACS) for CD44 (99.9 0.2%), CD73 (96.5 6.6%), CD90
(98.5 1.6%), and CD105 (97.8 2.0%). CD45 antigen expres-
sion was negative (5.2 1.0%).
The quality of the human DBM was confirmed by a
significant reduction of the calcium content (47 116 vs
2615 890mg/dL of calcium corresponding to a mean demi-
neralization of 98%; P< 0.005) and by significant higher in
vivo osteogenesis (12 5 vs 1 3% of the explanted graft with
osteoinductivity; P< 0.05) in comparison to non-DBM,
respectively.
Clinical Safety and Efficacy
A mean of 16 4 million ASCs per patient was available
by the end of P3 (within 41 6 d), which was sufficient for
seeding into three 150-cm2 culture flasks for P4 (Table 1). The
osteogenic differentiation was then induced at P4 for 15 days
(when ASCs were confluent) before supplementation of DBM
at 10mg/mL to create the 3D structure. All grafts demonstrated
a 3D structure before implantation. The 3D graft was implanted
at day 112 26 after adipose tissue procurement, consistent
with the preoperative chemotherapy course. Three grafts of
3 3 cm2 (1 graft per 150-cm2 flask) were produced per patient
from ASCs supplemented with DBM 10mg/mL (Fig. 1). The
final product was stable and did not rupture with forceps
manipulation.
No adverse event occurred at the site of adipose
tissue biopsy.
The 3D structure was verified for each graft (preimplanta-
tion) by histomorphometric potency testing scored based on
staining for osteogenic phenotype and mineralization of the
matrix.
The complex clonal numerical and structural chromosomal
aberrations detected in the bone tumor cells (Table 2) were not
detected in the ASCs developed for each graft at P1 and P4 (both
undifferentiated and differentiated status). Minor clones with
structural aberrations detected in the undifferentiated ASCs at
P4 were absent from the differentiated ASCs (Fig. 2).
No acute side effects such as inflammatory reaction, pain,
or wound nonhealing were reported (Figs. 3 and 4).
No patient had complications during follow-up, but patient
#2 underwent allograft removal because of intercalary allograft
infection more than 10 months posttransplantation. No long-
term complications were observed for patients 1 and 3 after a
mean follow-up of 37 months. For both patients, ossification
was rapidly initiated around the Phenix prosthesis and the bone
allograft, respectively (Fig. 3). The junction of the native bone
and the bone substitute began at 3 months postimplantation and
remained consolidated up to 47 months. The stabilization of the
allografts led to a normal quality of life more than 3 years
postimplantation (Fig. 3B).
Although no acute complication was reported for patients
with bone nonunion (patients 4–6), one case required material
removal due to sepsis following screw and plate infection by
Staphylococcus aureus at 10 months posttransplantation. No
sign of bone consolidation was found. For patient #4, a surgical
revision was performed at 9 months, due to incomplete or
inefficient bone consolidation. In bone nonunion within an
erythroblastopenia context, the bone consolidation was con-
firmed at 10 months postimplantation and maintained up to 29.8
months (Fig. 4).
No abnormal ectopic bone development was found radi-
ologically after a mean of 32 months postimplantation for all
patients (n¼ 6).
DISCUSSION
The combination of osteoprogenitor ASCs and growth
factors included in osteoconductive DBM demonstrated the
feasibility of manufacturing a clinical batch of 3D scaffold-
free autologous and osteogenic graft; the safety of differentiated
stem cells and growth factors in an oncological context; and the
efficacy of surgical reconstruction of a large bone defect in a
stringent clinical context, specifically bone pseudarthrosis and
bone tumor resection.
The most important outcome of this study is the proof of
concept in terms of feasibility for manufacturing a scaffold-free
3D implant from human autologous ASCs differentiated into an
osteogenic phenotype with DBM. For clinical application of this
advanced therapy of medicinal products, all procedures were
validated using human ASCs (following GMPs) and DBM with
the goal of being able to uniformly reproduce the manufacture of
a structural and stable 3D implant in all patients despite clinical
constraints, such as the timing of adjuvant chemotherapy, the
Medicine  Volume 94, Number 50, December 2015 Scaffold-free Graft for Bone Reconstruction
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved. www.md-journal.com | 5
T
A
B
L
E
2
.
G
e
n
e
ti
c
A
n
a
ly
si
s
o
f
A
S
C
s
fo
r
C
lin
ic
a
l
A
p
p
lic
a
ti
o
n
—
P
at
ie
n
t
G
en
et
ic
A
n
al
ys
is
of
N
at
iv
e
D
is
ea
se
U
n
d
if
fe
re
n
ti
at
ed
A
S
C
s
O
st
eo
ge
n
ic
A
S
C
s
1
K
ar
y
o
ty
p
e:
4
6
,
X
Y
[2
0
]
—
F
IS
H
:
tr
i
an
d
te
tr
as
o
m
ie
s
1
2
ce
n
/
1
2
q
1
5
(3
1
%
),
1
7
ce
n
/1
7
p
1
3
(5
2
%
),
2
2
q
1
2
(3
7
%
),
an
d
8
ce
n
(2
7
%
)—
1
3
q
1
4
/R
B
1
d
el
et
io
n
(5
7
%
)
N
d
K
ar
y
o
ty
p
e:
4
6
,
X
Y
[2
0
]
—
F
IS
H
:
te
tr
as
o
m
ie
s
(
2
%
–
3
%
)
2
K
ar
y
o
ty
p
e:
3
7
3
8
,
X
,-
Y
,
ad
d
(1
q
),
-1
,
-2
,
-3
-,
3
,
-4
,
ad
d
(5
q
),
ad
d
(6
q
),
-8
,
-9
,
-1
0
,
-1
1
,
-1
1
,
ad
d
(1
2
p
),
d
el
(1
2
p
),
-1
3
,
ad
d
(1
5
p
),
-1
6
,
ad
d
(1
7
p
),
-1
8
,
ad
d
(1
9
p
),
-1
9
,
ad
d
(2
0
q
),
-2
0
,
ad
d
(2
1
p
),
-2
1
,
ad
d
(2
2
p
),
-2
2
,
m
ar
1
m
ar
1
1
[c
p
5
]/
7
4
–
7
8
<
4
n
>
,
id
em
[2
]
—
F
IS
H
:
m
o
n
o
so
m
ie
s
9
ce
n
an
d
9
p
2
1
/
C
D
K
N
2
A
/C
D
K
N
2
B
,
1
3
q
1
4
/R
B
1
,
2
2
q
1
2
/E
W
S
R
1
(2
8
%
–
4
2
%
);
p
o
ly
so
m
ie
s
(m
ai
n
ly
te
tr
as
o
m
ie
s)
8
ce
n
,
1
2
ce
n
,
1
2
q
1
5
/
M
D
M
2
,
1
7
p
1
3
/T
P
5
3
,
an
d
2
2
q
1
2
/E
W
S
R
1
(7
%
–
1
4
%
)
K
ar
y
o
ty
p
e:
4
6
,
X
Y
[5
0
]
w
it
h
h
ig
h
n
u
m
b
er
o
f
ch
ro
m
o
so
m
al
b
re
ak
ag
e
at
th
e
sa
m
e
lo
ca
ti
o
n
ch
t(
3
)(
q
1
3
)
—
F
IS
H
:t
et
ra
so
m
ie
s
8
ce
n
,9
ce
n
,9
p
2
1
/
C
D
K
N
2
A
,
an
d
D
C
K
N
2
B
(2
%
–
3
%
)
N
d
3
K
ar
y
o
ty
p
e:
4
8
,
X
Y
,þ
8
,t
(1
1
;2
2
)
(q
2
4
;q
1
2
),
þ1
2
[7
]/
4
9
,i
d
em
,þ
2
[2
]/
4
9
,i
d
em
,þ
2
0
[1
]/
4
8
,
X
Y
,i
d
em
,þ
ad
d
(1
2
p
)[
2
]/
4
6
,X
Y
[6
]—
F
IS
H
:
F
L
I1
-E
W
S
R
1
fu
si
o
n
(7
7
%
)
T
ri
so
m
ie
s
8
ce
n
(6
8
%
),
1
2
ce
n
,
an
d
1
2
q
1
5
/M
D
M
2
(4
6
%
)
K
ar
y
o
ty
p
e:
4
7
,
X
Y
,þ
7
[1
0
]/
4
6
,
X
Y
[2
6
]—
F
IS
H
:
tr
is
o
m
y
7
ce
n
(5
.5
%
)
te
tr
as
o
m
ie
s
7
ce
n
an
d
8
ce
n
(2
%
)
K
ar
y
o
ty
p
e:
4
6
,
X
Y
,t
(1
4
;1
5
)
(q
3
2
;q
1
1
.2
)[
6
]/
4
6
,t
(X
;1
5
)
(p
1
1
.2
;q
2
2
),
Y
[2
]/
4
6
,
X
Y
[9
2
]—
F
IS
H
:
tr
is
o
m
y
7
ce
n
(1
2
.5
%
);
te
tr
as
o
m
ie
s
7
ce
n
an
d
8
ce
n
(8
%
)
4
K
ar
y
o
ty
p
e:
4
6
,
X
Y
[2
0
]—
F
IS
H
:
n
o
rm
al
p
at
te
rn
fo
r
8
ce
n
,
9
ce
n
,
9
p
2
1
/C
D
K
N
2
A
,
an
d
C
D
K
N
2
B
,
1
3
q
1
4
/R
B
1
,
1
7
ce
n
,
1
7
p
1
3
/
T
P
5
3
,
an
d
2
2
q
1
2
/E
W
S
R
1
K
ar
y
o
ty
p
e:
4
7
,
X
Y
,þ
7
[2
]—
F
IS
H
:
tr
is
o
m
y
7
ce
n
(6
.5
%
)
te
tr
as
o
m
ie
s
7
ce
n
an
d
8
ce
n
(2
.5
%
)
K
ar
y
o
ty
p
e:
4
6
,
X
Y
[1
8
]—
F
IS
H
:
te
tr
as
o
m
ie
s
7
ce
n
an
d
8
ce
n
(1
0
%
),
n
o
tr
is
o
m
y
7
ce
n
5
N
d
K
ar
y
o
ty
p
e:
4
6
,
X
Y
[1
9
]/
9
2
,
X
X
Y
Y
[1
]
—
F
IS
H
:
n
o
d
et
ec
ta
b
le
te
tr
as
o
m
ie
s
7
ce
n
(0
.5
%
)
an
d
8
ce
n
n
o
r
tr
is
o
m
y
7
ce
n
K
ar
y
o
ty
p
e:
4
6
,
X
Y
[2
0
]—
F
IS
H
:
n
o
d
et
ec
ta
b
le
te
tr
as
o
m
ie
s
7
ce
n
(1
%
)
&
8
ce
n
n
o
r
tr
is
o
m
y
7
ce
n
6
K
ar
y
o
ty
p
es
o
n
b
o
n
e
m
ar
ro
w
ce
ll
s
in
2
0
0
2
,
2
0
0
3
,
2
0
0
7
:
n
o
rm
al
K
ar
y
o
ty
p
e:
4
6
,
X
Y
,d
el
(3
)
(p
1
4
)[
1
]/
4
6
,
X
Y
[3
8
]/
9
2
,
X
X
Y
Y
[1
]—
F
IS
H
:
te
tr
as
o
m
ie
s
7
ce
n
an
d
8
ce
n
(3
%
),
n
o
d
et
ec
ta
b
le
tr
is
o
m
y
7
ce
n
K
ar
y
o
ty
p
e:
4
6
,
X
Y
,d
el
(3
)(
p
1
4
)[
2
]/
4
6
,
X
Y
[3
8
]—
F
IS
H
:
te
tr
as
o
m
ie
s
7
ce
n
an
d
8
ce
n
(4
%
),
tr
is
o
m
y
7
ce
n
(2
.5
%
)
A
S
C
s
¼
ad
ip
o
se
-d
er
iv
ed
st
em
ce
ll
s,
ce
n
¼
ce
n
tr
o
m
er
e,
F
IS
H
¼
fl
u
or
es
ce
n
ce
in
si
tu
h
y
b
ri
d
iz
at
io
n
.
K
ar
y
o
ty
p
es
an
d
F
IS
H
o
f
p
at
ie
n
ts
1
to
3
w
er
e
co
m
p
ar
ed
w
it
h
in
di
v
id
u
al
co
n
tr
o
lp
at
ie
n
ts
(6
–
1
3
y
o
ld
w
it
h
2
co
n
g
en
it
al
an
d
1
ac
q
u
ir
ed
b
o
n
e
p
se
u
d
ar
th
ro
si
s)
.N
o
n
at
iv
e
tu
m
o
r
ab
n
o
rm
al
it
ie
s
w
er
e
fo
u
n
d
in
u
n
d
if
fe
re
n
ti
at
ed
an
d
d
if
fe
re
n
ti
at
ed
A
S
C
s
fo
r
p
at
ie
n
ts
1
–
to
3
.
N
o
d
if
fe
re
n
ce
w
as
fo
u
n
d
b
et
w
ee
n
ex
p
an
de
d
an
d
d
if
fe
re
n
ti
at
ed
A
S
C
s
fr
om
p
at
ie
n
ts
w
it
h
a
b
o
n
e
tu
m
o
r
an
d
b
o
n
e
p
se
u
da
rt
h
ro
si
s.
Dufrane et al Medicine  Volume 94, Number 50, December 2015
6 | www.md-journal.com Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 2. Genetic stability of ASCs in bone tumor context. Karyotype and FISH (FLI1-EWSR1 double fusion probe) analyses for the native
tumor (A, arrow: t[11;22] [q24;q12]) and undifferentiated (B) and differentiated (C, arrow: t[14;15] [q32;q11.2]) ASC at P4 for patient 3:
the FLI1-EWSR1 double fusion signals detected on the native tumour cells (A) were not detected in the ASCs at P4 (B, C), but minority
tetrasomies of both probes by FISH suggesting tetraploidywere found for undifferentiated ASCs (B). Initial trisomy 8was not detected, but
minority tetraploidy (detected by the tetrasomies of both probes by FISH) was found after osteogenic differentiation (C) in comparison to
the native tumor tissue. ASCs¼ adipose-derived stem cells, FISH¼ fluorescence in situ hybridization, P4¼passage 4.
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schedule of operating room access, and interdonor variability. A
mean of 3.7 months for graft manufacture was compatible for
clinical implantation, taking into consideration some delays due
to patient state (minimum of 80 vs maximum of 143 d for
patients 2 and 3, respectively). Another important issue for the
clinical feasibility is the size of the implant generated to fill the
bone defect. The size of generated 3D bone-like tissue (a mean
of 12.6 cm3 for the 3 grafts) was significantly increased by
nearly 6 times (compared to 2 cm3 of native adipose tissue), and
it was always sufficient to fill the bone defect, which was a
function of the clinical indication.
The primary issue for the clinical application of advanced
cell therapy remains the safety of the patient. Although human
MSC (deficient for p53 and/or Rb) failed to induce tumor
formation in vivo, suggesting the safety of these cells in clinical
application, Perrot et al33 postulated a risk associated with
autologous fat graft implantation in a postneoplasic context,
especially for osteosarcoma. No tumor recurrence was observed
FIGURE 3. Bone defect at the junction between the native bone tissue and the intercalary allograft (after tumor resection at the right
tibia). A, No patient had complications during follow-up, but patient #2 underwent allograft removal because of intercalary allograft
infection more than 10 months posttransplantation. No long-term complications were observed for patients 1 and 3 after a mean follow-
up of 37months. B, The graft was placed at the direct junction between both tissues without any fixationmaterial. The total consolidation
was demonstrated at 24.3 months, the total bridge between the native tissue and the allograft was confirmed at 33 months
postimplantation (as demonstrated by nuclear magnetic resonance), and the consolidation is currently maintained up to 47 months
posttransplantation. A complete return to normal quality of life for patient #3 was confirmed after 3 years.
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in our series more than 3 years posttransplantation. Controversy
exists concerning the potential for spontaneous transformation
of MSCs after prolonged ex vivo culture, but several studies
reported that MSCs have limited tendencies to develop
tumors.34–36 In the context of the pediatric population, especi-
ally in cases of bone tumor, all precautions were taken to
guarantee ASC expansion and differentiation before transplan-
tation. In contrast to native bone tumor, which harbored com-
plex genomic alterations, FISH analysis revealed minor rates
(near the detection threshold) of chromosomal aneuploidy,
mainly tetrasomies, suggesting tetraploidy as classically
observed in cultured cells (around the cut-off of 4.5% and
different from the initial tumor clone) and known to be non-
tumorigenic.37 The clonal chromosomal and structural aberra-
tions detected in the karyotypes of 2 patients were not
associated with a selective growth advantage in vitro. In a
context of chronic wound healing with undifferentiated human
ASCs, we previously demonstrated minor rates (near the
FIGURE 4. Bone nonunion in a case of congenital pseudarthrosis. A, No acute complicationwas reported for patients with bone nonunion
(patients 4–6), 1 case requiredmaterial removal due to sepsis following screw and plate infection byStaphylococcus aureus at 10months
posttransplantation. No sign of bone consolidation was found. For patient #4, a surgical revision was performed at 9 months, due to
incomplete or inefficient bone consolidation. In bone nonunion within an erythroblastopenia context, the bone consolidation was
confirmed at 10months postimplantation andmaintained up to 29.8months. B, The 3D graft can easily be placed in the large bone defect
of the left ulna of patient 4. Bone nonunion, found on the right tibia of patient 6, was initiated at 6 months postimplantation and
consolidated up to 29.8 months. 3D¼3-dimensional.
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detection threshold) of chromosomal aneuploidy up to passage
16 (cut-off 4.5%) and the absence of adverse events in
immunodeficient animal recipients (1 or 3 months postimplan-
tation) and in patients (up to 22 months after implantation). In
this study, the in vivo oncologic safety was confirmed by the
absence of adverse events in patients up to 3 years after
implantation; ASC delivery after a shorter in vitro culture
(P4), thus avoiding the selection of tumor cell clones; and
the stabilization of the genome by osteogenic differentiation.38
The implantation of a 3D osteogenic-like graft was suffi-
cient to provide long-term safety as well as proof of efficacy in
extreme clinical conditions. All manufactured 3D grafts were
easily handled and implanted (without any additional fixation
materials) in a defined and regular space (eg, the junction
between the intercalary allograft and native bone) or in an
irregular defect as found after tumor resection or in pseudar-
throsis, respectively. Although the final 3D graft is not intended
to directly restore the native bone mechanical properties, the
low mineral content of the final 3D product (which is only a
mean of 18% of that found in human adult trabecular bone: 277
vs 2876mg/cm3, respectively, data not shown) confers an
optimal malleability for surgical implantation.39 No side effects
can be related to the 3Dgraft. The cases of reported infection
were associated with the intercalary allograft and the fixation
material contamination at the peri or postoperative time. The
microbiological control of the 3Dgraft (at the time of implan-
tation) and the culture media (used as vehicle for the transpor-
tation between clean room and operative room) did not reveal
contamination. Bus et al5 recently demonstrated that bone
nonunion (between intercalary and native bone) remains the
major cause (40% of patients) of second surgical intervention
(with the use of cancellous bone allograft at 1 y after the initial
surgery) to facilitate the union of allograft–host junctions after
tumor resection. Although no junction (by x-ray) was found at 6
months after graft implantation (which can be associated to a
lower degree of mineralization of the 3D graft compared to
native bone), the 3D graft was found to promote irreversible
bone consolidation up to 47 months, restoring normal quality of
life, especially for patients #1 and #3. Although ASCs survived
and promoted in vivo osteogenesis in bone nonunion (conge-
nital or acquired) up to 29.8 months posttransplantation, which
is characterized by low oxygen tension, fibrosis, and absence of
a local favorable environment (low level of local and systemic
growth factors, such as fibroblast growth factor 2), a lower rate
of success was found in this category of patients (certainly due
to the native pathophysiology of the pseudarthrosis).40
Although in vivo histological analysis could not be performed
for ethical reasons, x-ray analysis demonstrated total consolida-
tion, which was initiated rapidly at 3 months postimplantation.
This observation coincides with our previous preclinical results
demonstrating in vivo consolidation of critical femoral size
bone defect at 6 months postimplantation, which was charac-
terized by endochondral and intramembranous ossification after
the 3D graft implantation.28
CONCLUSIONS
We report for the first time that autologous ASCs can be
fully differentiated into a 3D osteogenic-like implant without
any scaffold. We demonstrated that this engineered tissue can
safely promote osteogenesis in extreme conditions of bone
nonunion, leading to restoration of bone anatomy and function,
with minor donor site morbidity and no oncological side effects.
Since bone nonunion incidence is increased due to comorbidity
factors (eg, type 2 diabetes, smoking), this technology must
demonstrate its potential in terms of clinical benefit in com-
parison to a gold-standard surgery (reduction of additional
interventions, reduction of morbidity); improved cost effective-
ness by the introduction of allogenic ASC source and auto-
mated/closed culture system to reduce the interbatch variability
and manufacturing costs (eg, clean room, quality control test-
ings, operator handling). A prospective controlled trial is
needed for clinical relevant indications to clinically assess
the 3D osteogenic-like implant.
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